Argentina and Mexico will produce the AstraZeneca COVID-19 vaccine for most of Latin America, Argentine President Alberto Fernandez said after a meeting with company executives involved in the project, according to a report by Expresspharma.india.
An agreement signed between British pharma company AstraZeneca and the biotechnology company mAbxience, part of the INSUD Group, includes transfer of technology to initially produce 150 million doses of the vaccine to supply all of Latin America with the exception of Brazil, the Argentine government said.
Marcelo Ebrard, Foreign Minister of Mexico said later on Twitter that the deal had been pushed by Fernandez and Andres Manuel Lopez Obrador, Mexican President. He said output of the vaccine could extend to 250 million doses.
AstraZeneca has long operations in Argentina. The company signed a deal with the foundation of Mexican billionaire Carlos Slim for production of the vaccine, which is expected to be delivered in the first half of 2021, pending Phase III studies and regulatory approvals.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze